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Surgical antibiotic prophylaxis (SAP) is recommended for the prevention of surgical site infections. 
However, there is a concern about adverse effects of SAP, such as antibiotic-associated diarrhea (AAD). 
To prevent AAD, administration of probiotics has been investigated. Although recent advances in next-
generation sequencing makes it possible to analyze the gut microbiome, the effect of probiotics on the gut 
microbiome in the patients with SAP remains unknown. To test a hypothesis that SAP influences the gut 
microbiome and probiotics prevent the influence, a randomized controlled study was conducted with 
patients who underwent spinal surgery at Nagasaki University Hospital. After obtaining informed 
consent, the patients were automatically classified into the non-probiotics group and the probiotics group. 
In the probiotics group, the patients took 1 g of Enterococcus faecium 129 BIO 3B-R, 3 times a day on 
postoperative days (PODs) 1 to 5. The feces of all patients were sampled before administration of SAP 
and on PODs 5 and 10. We compared alpha and beta diversity and differential abundance analysis of the 
gut microbiome before and after SAP. During the study period, a total of 33 patients were evaluated, 
comprising 17 patients in the non-probiotics group and 16 in the probiotics group. There was no 
significant difference between the groups regarding patient characteristics. In alpha and beta diversity, 




operational taxonomic unit level, Streptococcus gallolyticus and Roseburia were significantly increased 
in the non-probiotics group and significantly decreased in the probiotics group.  
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  Surgical site infections (SSIs) are among the most common healthcare-associated infections (HAIs), 
with an incidence rate at 31.0% of all HAIs among hospitalized patients [1]. In spinal surgery, the 
incidence rate of SSIs rates range from 0.72% for laminectomy with no risk factors to 8.7% for refusion 
in patients with risk factors early SSI is a frequent complication, with incidence rates ranging from 2% to 
10%.[2] Since several meta-analyses revealed that surgical antibiotic prophylaxis (SAP) can reduce the 
risk of SSIs [3–5], SAP has been recommended in guidelines of the Centers for Disease Control and 
Prevention (CDC) [6].  
Despite the CDC recommendation, there is concern about the adverse effects of SAP, such as allergy, 
anaphylaxis, nausea, diarrhea, and emergence of antibiotic resistance. Among these adverse effects, 
antibiotic-associated diarrhea (AAD) including Clostridioides difficile infection (CDI) is important, 
because owing to because its frequency has risen and severity.[7] Because Since AAD results from 
changes in the gut bacteria resulting from administration of antibiotics, probiotics, such as Enterococcus 
faecium 129 BIO 3B-R, Enterococcus faecalis BIO-4R, Clostridium butyricum, have been used 
as drugs to prevent the occurrence of AAD in Japan. In culture, post-antibiotic gut bacteria with addition 




Nevertheless, it is difficult to assess the actual effect of probiotics on gut bacteria because there are many 
unculturable bacteria in stool samples [9].  
Recently, with the development of new technologies like next-generation sequencing (NGS), it has 
become possible to detect and analyze gut bacteria, including unculturable bacteria (the gut microbiome). 
In the past decade, there have been many reports on the relationship between various diseases and 
changes in the gut microbiome. These studies have revealed that the gut microbiome has an important 
role in human health and disease [10]. However, there are few reports on the influence of antibiotics or 
the effect of probiotics on the gut microbiome. In particular, the influence of SAP on gut microbiota 
remains unknown. In this study, we investigated the effect of Enterococcus faecium 129 BIO 3B-R on 







Material and methods 
Study design 
  We conducted a prospective randomized controlled study at Nagasaki University Hospital between 
July 2016 and October 2017. Forty adult patients who underwent spinal surgery in the Department of 
Orthopedic Surgery participated in this study. Patients were excluded if they had an allergy to probiotics 
preparations, a history of antibiotics administration within 1 month prior to hospitalization, 
administration history of a probiotics preparation within 1 month prior to hospitalization, 
inflammatory bowel diseases, or pregnancy. After obtaining informed consent, the patients were 
automatically classified into two groups using the permuted block method created by primary 
investigator: the non-probiotics group and the probiotics group. The patients classified into the 
probiotics group took 1 g of Enterococcus faecium 129 BIO 3B-R (Biofermin Pharamceutical 
Ltd., Kobe, Hyogo, Japan), 3 times a day on postoperative days (PODs) 1 to 5. All patients 
underwent surgery and were administered antimicrobial prophylaxis (SAP) on the decision of a physician. 
The feces of all patients were sampled before administration of SAP (pre-operatively) and on PODs 5 and 
10. In the non-probiotics group, one patient was excluded for withdrawal of consent and another patient 




consent and two patients were excluded for a lack of sample. Finally, we analyzed feces samples obtained 
from 33 patients, comprising 17 patients in the non-probiotics group and 16 patients in the probiotics 
group (Fig. 1). The primary outcome measure in this study was diversity difference between the non-
probiotics and probiotics groups at PODs 5 and 10. The secondary outcome measures in this study was 
differences in bacterial species between the non-probiotics and probiotics groups at PODs 5 and 10. 
 
Statistical analysis of patients’ background 
The backgrounds and clinical course of all included patients were investigated until discharge from the 
hospital. In a comparative study of the backgrounds of all included patients, we used IBM SPSS version 
25 (IBM Japan, Tokyo, Japan) for all statistical analyses, which were unpaired, two-tailed, and tests of 
significance. The statistically significant alpha level was set at ≤0.05. Fisher’s exact test was used to 
compare categorical variables. Continuous variables were expressed as the mean ± standard deviation 
(SD), and compared using the Student t-test. 
 




Fecal samples were stored at −80°C until further analysis. DNA was extracted using a ZR Fecal DNA 
MiniPrep Kit (Zymo Research, Irvine, CA, USA), according to the manufacturer’s instructions. The V1-
V2 region of bacterial 16S rRNA genes was amplified using the following primers: forward (5’-
AGAGTTTGATYMTGGCTCAG-3’) with the Ion A adapter and sample-specific 13-base barcode 
sequences, and reverse (5’-TGCTGCCTCCCGTAGGAGT-3’) with the Ion trP1 adapter sequence [11]. 
Emulsion PCR and enrichment were performed using an Ion PGM HiQ View OT2 Kit (Thermo Fisher 
Scientific, Waltham, MA, USA). The enriched samples were loaded onto an Ion 318 chip and sequencing 
was performed using the Ion Torrent Personal Genome Analyzer with an Ion PGM HiQ View Sequencing 
Kit (Thermo Fisher Scientific, Waltham, MA, USA). 
 
Sequence analysis 
  The sequencing reads were analyzed using CLC Genomics Workbench version 11.0.1 and CLC 
Microbial Genomics Module version 3.6.11 (QIAGEN N. V., Venlo, Netherlands). After removing the 
primer sequences and trimming the read length to less than 240 bp, a total of 22,089,551 reads were 




units (OTUs) with 97% similarity and then assigned using Greengenes version 13.8. We removed OTUs 
with low abundance, combined abundance less than 10, or less than 0.01% of total reads. 
The number of OTUs, Shannon index, and Simpson’s index (alpha diversity) were calculated; the data 
were visualized as box and whisker plots. To compare alpha diversity, the data were analyzed using 
Tukey’s honestly significant difference with IBM SPSS. The statistically significant alpha level was set 
as ≤0.05. Beta diversity was calculated and visualized with principal coordinate analysis (PCoA) plots 
using unweighted and weighted UniFrac distances. To compare beta diversity, the data were analyzed in 
PERMANOVA analysis using the CLC Microbial Genomics Module, and the statistically significant 
alpha level was set as ≤0.05 in false discovery rate (FDR) p value.  
To reveal the change of abundance in each group, abundance pre-operatively and on PODs 5 and 10 in 
each group was compared using differential abundance analysis with the CLC Microbial Genomics 
Module, and statistical significance was set to alpha ≤0.05 in FDR p value. To reveal the effect of 
probiotics, we defined OTUs that were significantly increased in the probiotics group and decreased in 
the non-probiotics group as positive responders; OTUs that were significantly decreased in the probiotics 
group and increased in the non-probiotics group were defined as negative responders. To identify the 




EzBioCloud 16S database [12]. When species showed pairwise similarity with OTUs, the scientific name 
of the higher taxonomic classification was used. 
 
Ethics 
  This study followed the principles set forth in the Declaration of Helsinki and was approved by the 
ethics committee of Nagasaki University Hospital (approval number, 16042503). This trial was registered 
in UMIN-CTR (reference number, UMIN000021718; date of full registration, 02/05/2016). Written 





Comparison of patient characteristics 
 During the study period, a total of 33 patients were evaluated, 17 patients in the non-probiotics group 
and 16 in the probiotics group (Fig. 1). Patient characteristics are shown in Table 1. There were no 




underlying diseases, and surgical site. Regarding SAP, all patients were administered cefazolin. The 
percentage of combination therapy with cefazolin and vancomycin was higher in the control group (n=4, 
23.5%) than that in the probiotics group (n=2, 12.5%), but there was no significant difference. The mean 
days of cefazolin administration in the non-probiotics group and the probiotics group was 3.3 ± 1.0 and 
3.0 ± 0.4, respectively. The patients were administered vancomycin once in the combination therapy. 
Postoperative complications occurred in the non-probiotics group only, where two patients had soft 
stools. Both patients were administered cefazolin and vancomycin and had soft stool at PODs 5. 
 
Alpha and beta diversity 
We identified a total of 629 OTUs. The average richness (observed OTUs) pre-operatively and on PODs 
5 and 10 was 220.71, 226.00, and 225.71 in the non-probiotics group and 247.56, 253.25, and 226.06 in 
the probiotics group, respectively (Fig. 2A). The average Shannon index pre-operatively and on PODs 5 
and 10 was 4.49, 4.33, and 4.40 in the non-probiotics group and 5.04, 4.88, and 5.00 in the probiotics 
group, respectively (Fig. 2B). The average Simpson’s index pre-operatively and on PODs 5 and 10 was 
0.87, 0.87, and 0.87 in the non-probiotics group and 0.92, 0.92, and 0.91 in the probiotics group, 




The beta diversity was visualized with a PCoA plot using unweighted and weighted UniFrac distances 
(Fig. 3). There was no significant difference among all combinations in PERMANOVA analysis with 
unweighted and weighted UniFrac distances. 
 
Changes of abundance in each group 
In differential abundance analysis at OTU level, the number of OTUs in the non-probiotics group that 
significantly increased on PODs 5 and 10 in comparison with the pre-operative period was 62 and 36, 
respectively; in the probiotics group, the number of OTUs on PODs 5 and 10 was 77 and 62, respectively. 
In the non-probiotics group, the number of OTUs that significantly decreased at PODs 5 and 10 in 
comparison with the pre-operative period was 89 and 30, respectively; in the probiotics group, the 
number of OTUs on PODs 5 and 10 was 66 and 46, respectively. Among OTUs, there were four positive 
and three negative responders (Table 2). Based on their sequence data, we identified the taxonomic names 
of positive and negative responders (Table 2). C. celatum and Eubacterium siraeum (two OTUs) were 
identified as positive responders on both PODs 5 and 10. The genus Enterobacter was identified as a 




PODs 5. Streptococcus gallolyticus subsp. pasteurianus and S. gallolyticus (subsp. gallolyticus or 




  Our findings regarding alpha and beta diversity indicated that administration of antibiotics SAP did not 
change the composition of the gut microbiome. In this study, all participants were administered cefazolin 
as monotherapy or in combination with vancomycin. In a previous study on the risk of Clostridioides 
difficile infection (CDI)CDI, the adjusted hazard ratio for first- and second-generation cephalosporins in 
CDI was 2.4 [13]. Investigation of an outbreak of CDI revealed that the incidence of CDI was 
significantly associated with the administration of cefazolin, in multivariate analysis [14]. However, in 
the report, the authors described that the association between cefazolin use and CDI rates is a 
mathematical relationship driven by the consistently high use of cefazolin, because they could achieve 
sustained control of a CDI outbreak without a change in the use of antibiotics[14]. Additionally, in a 
randomized control trial of SAP with cefazolin, no patients experienced CDI [15]. Our data findings 




cefazolin did not influence the gut microbiome, and probiotics did not show efficacy for improving gut 
microbiota. However, we found a potentially influential factor among our results. As shown in Fig. 3, the 
composition of the gut microbiome differed substantially among pre-operative samples from study 
participants. We planned this prospective study to include patients undergoing spinal surgery, as we 
expected that most of these patients would have fewer underlying diseases than those undergoing other 
types of surgery. Contrary to expectations, 45.5% of the patients participating in this study had 
underlying diseases. The composition of gut microbiota might depend on underlying diseases [10]. Thus, 
there is a possibility that the underlying diseases in our patients could account for the variation in the pre-
operative composition of gut microbiota. 
  On the other hand, Iin the differential abundance analysis at OTU level, S. gallolyticus (two strains) 
and Roseburia were identified as negative responders, which were significantly decreased in the 
probiotics group and increased in the non-probiotics group. S. gallolyticus (previously S. bovis) has long 
been associated with colorectal cancer and infective endocarditis [16,17]. The strain identified as 
Roseburia was homologous to R. cecicola and R. faecis. These species have been isolated from murine 
cecal mucosa and human stool samples, respectively [18,19]; however, there are no reports on their 




at PODs 5 only. C. celatum and Eubacterium siraeum were identified as positive responders, which were 
significantly increased in the probiotics group and decreased in the non-probiotics group, at both PODs 5 
and 10, and Enterobacter (KN150796, E. soli, or E. asburiae) was identified as a positive responder at 
PODs 5 only. C. celatum is a gram-positive rod that has been isolated from healthy adults [20]. Although 
there has been only one report of C. celatum infection in two patients [21]; its pathogenicity in the human 
intestine remains uncertain. There have been no reports on the pathogenicity and function of E. siraeum 
and Enterobacter in the human intestine. At this time, it is uncertain whether the effect of probiotics on 
negative responders (Roseburia) and positive responders (C. celatum, E. siraeum, and the genus 
Enterobacter) has any implications for patients administered SAP because the pathogenicity and function 
of these bacteria in the human intestine remains unknown. However, considering the pathogenicity of S. 
gallolyticus and the influence of SAP through PODs 10, the effect of probiotics shown in this study 
seems to be important. 
  The effect of probiotics has been studied for a long time. In a meta-analysis of the effect of probiotics 
on gastrointestinal diseases, a significant effect of probiotics has been observed in many gastrointestinal 
diseases, including AAD [22]. A previous report stated that administration of Lactobacillus rhamnosus 




antibiotics [23]; however, when children and adults were evaluated separately, this reduction was not 
observed in adults [23]. In a meta-analysis of the effect of probiotics on CDI prevention in adults and 
children, probiotics were effective in preventing CDI, with moderately strong evidence (risk ratio 0.40, p 
< 0.001) [24]. In the analysis, the risk ratio of CDI prevention with Saccharomyces boulardii and many 
combinations of various species showed a significant reduction in risk whereas Saccharomyces 
cerevisiae, LGG, Lactobacillus acidophilus, L. plantarum, L. reuteri, and L. casei Shirota did not have 
significant effects [24]. Based on these studies, the effect of probiotics on AAD, including CDI, seems to 
differ from species to species. In this study, we used E. faecium 129 BIO 3B-R. This bacterium has been 
used as a probiotic in Japan for patients who are administered antibiotics. Although enterococci, such as 
E. faecium and E. faecalis, are important nosocomial pathogens, they produce lactic acid and are used as 
probiotics. Several clinical studies have reported that enterococci probiotics have a significant effect in 
patients with AAD [25]. In this study, two patients (11.8%) had soft stools after surgery in the non-
probiotics group whereas there no patients had soft stools in the probiotics group. Even though there was 
no significant difference between the groups, E. faecium might prevent the occurrence of AAD.  
  There were some limitations in this study. First, as discussed previously, the composition of gut 




condition influenced the results with respect to alpha and beta diversity. Further investigation with 
comparable preoperative conditions is needed to ascertain whether SAP indeed influences the gut 
microbiome. Second, there has been no confirmation of the pathogenicity and function of Roseburia, C. 
celatum, E. siraeum, and the genus Enterobacter. It is therefore difficult to assess the influence of SAP 
and the effect of probiotics in differential abundance analysis at the OTU level. Third, to date, there is no 
standard analytical method for the gut microbiome. We analyzed gut microbiota using commercial 
software and a widely recognized 16S rRNA gene database. However, there are many software programs 
and databases used for analysis of the gut microbiome, which might produce different results. Finally, 
two patients had soft stools, but no microbiological tests, including antigen testing for CDI, were 
performed for these stool samples.  
 
Conclusions 
Our findings showed that SAP did not influence the composition of the gut microbiome, but the 
relative abundance of S. gallolyticus was increased after SAP. In contrast, administration of probiotics 
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Figure 1. Participant flow diagram 
Participant flow diagram showing progression through phases of the randomized controlled trial.  
PODs, postoperative days; NGS, next-generation sequencing. 
 
Figure 2. Alpha diversity  
Box and whisker plot of the alpha diversity indices for richness (observed OTUs; A), Shannon index (B), 
and Simpson’s index (C). There was no significant difference between the groups with respect to 
richness, Shannon index, and Simpson’s index.  
PODs, postoperative days; OTU; operational taxonomic unit. 
 
Figure 3. Beta diversity 
Beta diversity was visualized using a principal coordinate analysis plot with unweighted (A and B) and 
weighted (C and D) UniFrac distances. There was no significant difference in all groups for the 
PERMANOVA test using unweighted and weighted UniFrac distances.  





Table 1. Comparison of patients’ characteristics 
Characteristics 
Non-probiotics 




Age, mean (SD) 66.0 (8.9) 66.6 (13.5) 0.888 
Sex, female 7 (41.2) 8 (50.0) 0.732 
Underlying diseases 13 (76.5) 13 (81.3) 1.000 
  Hypertension 8 (47.1) 8 (50.0) 1.000 
  Dyslipidemia 6 (35.3) 6 (37.5) 1.000 
  Diabetes mellitus 2 (11.8) 6 (37.5) 0.118 
  Cerebrovascular diseases 2 (11.8) 1 (6.3) 1.000 
  Rheumatic arthritis 2 (11.8) 0 (0.0) 0.485 
  Others 6 (35.3) 5 (31.3) 1.000 
Site of operation    
  Cervical spine 7 (41.2) 4 (25.0) 0.465 
  Thoracic spine 1 (5.9) 1 (6.3) 1.000 
  Lumbar spine 9 (52.9) 11 (68.8) 0.481 
Antimicrobial prophylaxis    
  Cefazolin 13 (76.5) 14 (87.5) 0.656 
  Cefazolin and vancomycin 4 (23.5) 2 (12.5) 0.656 
  Administration period, day, mean (SD) 3.3 (1.0) 3.0 (0.4) 0.270 
Change of antimicrobial agents 2 (11.8) 0 (0.0) 0.485 
Postoperative complication    
  Soft stool 2 (11.8) 0 (0.0) 0.485 





Table 2. Positive and negative responder to probiotics 
OTUs name (specific number) 






Top hit taxonomy 
(similarity, %) 
Positive responder at PODs 5    
Clostridiales_o (186984) -89.7 70.8 Clostridium celatum (99.1) 
Enterobacteriaceae_f (668514) -29.0 49.0 Enterobacter_g (99.1) 
Ruminococcus_g (187181) -187.6 9628.2 Eubacterium siraeum (100) 
Ruminococcus_g (291902) -38.3 599.2 Eubacterium siraeum (99.1) 
Positive responder at PODs 10    
Clostridiales_o (186984) -163.7 -163.7 Clostridium celatum (99.1) 
Ruminococcus_g (187181) -152.5 -152.5 Eubacterium siraeum (100) 
Ruminococcus_g (291902) -16.5 -16.5 Eubacterium siraeum (99.1) 
Negative responder at PODs 5    
Ruminococcus_g (547223) 34.2 -20.9 Roseburia_g (97.3) 
Negative responder at PODs 10    
Streptococcus_g (290759) 913.4 -265.2 
Streptococcus gallolyticus 
subsp. pasteurianus (100) 
Streptococcus_g (328283) 1600.3 -151.7 
Streptococcus gallolyticus 
(100) 
Positive responders, OTUs that were significantly increased in the probiotics group and decreased in the 
non-probiotics group; negative responders, OTUs that were significantly decreased in the probiotics 
group and increased in the non-probiotics group; PODs, postoperative days; g, genus; s, species; o, order; 
f, family; NS, not significant. 
Forty patients participated in this study
One patient was excluded for 
administration history of probiotics
Random allocation
Nineteen patients were
classified into non-probiotics group
Twenty patients were
classified into probiotics group
One patient was 
excluded for 
withdraw of consent
Two patients were 
excluded for 
withdraw of consent
• Administration of antimicrobial prophylaxis
• Sampling feces pre-operatively and on 
PODs 5 and 10
• Postoperative administration of antibiotics-
resistant lactic acid bacteria for 5 days 
between PODs 6 and 10
• Administration of antimicrobial prophylaxis
• Sampling feces pre-operatively and on 
PODs 5 and 10
Two patients were 
excluded for lack of 
samples
One patient was 
excluded for lack of 
samples
Fifty one samples from 17 patients 
were analyzed by NGS
Forty eight samples from 16 patients 
were analyzed by NGS
Figure 1. Participant flow diagram
Participant flow diagram showing progression through phases of the randomized controlled trial. 
PODs, postoperative days; NGS, next-generation sequencing.
Figure 2. Alpha diversity
Box and whisker plot of the alpha diversity indices for richness (observed OTUs; A), Shannon index (B), and 
Simpson’s index (C). There was no significant difference between the groups with respect to richness, Shannon 
index, and Simpson’s index. 
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Figure 3. Beta diversity
Beta diversity was visualized using a principal coordinate analysis plot with unweighted (A and B) and weighted (C 
and D) UniFrac distances. There was no significant difference in all groups for the PERMANOVA test using 
unweighted and weighted UniFrac distances. 
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